A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.

Authors

Michael J. Jelinek

University of Chicago, Department of Medicine, Comprehensive Cancer Center, Chicago, IL

Michael J. Jelinek , Nathan R. Foster , Alexander J. Zoroufy , Jonas A. De Souza , Gary K. Schwartz , Pamela N. Munster , Tanguy Y. Seiwert , Everett E. Vokes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.

First Author: Florence Atrafi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).

First Author: George Somlo

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.

First Author: George Somlo

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.

First Author: George Somlo